Related Experiment Video

Updated: Aug 17, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke

Daniel G Hackam1, Moira K Kapral

  • 1From the Division of Clinical Pharmacology, University of Toronto, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|September 21, 2004
PubMed

Insights

Secondary stroke prevention strategies are evolving beyond traditional methods. This review examines newer pharmacotherapies and interventions for reducing recurrent cerebrovascular events and improving patient outcomes.

Area of Science:

  • Neurology
  • Cardiology
  • Vascular Medicine

Background:

  • Stroke is a major global cause of death and disability.
  • Survivors face high risks of recurrent cerebrovascular events and other vascular conditions.
  • Established secondary prevention includes aspirin, warfarin, and carotid endarterectomy.

Purpose of the Study:

  • To review emerging pharmacotherapies for secondary stroke prevention.
  • To assess the clinical significance of novel treatment options.
  • To provide evidence-based recommendations for preventing recurrent stroke.

Main Methods:

  • Literature review of recent studies on stroke prevention therapies.
  • Analysis of evidence for antiplatelet agents, lipid-lowering drugs, and antihypertensives.
  • Evaluation of B vitamins and direct thrombin inhibitors for specific patient groups.

Main Results:

  • Newer antiplatelet agents offer expanded therapeutic options.
  • Lipid-lowering drugs and blood pressure management are crucial.
  • Emerging treatments like B vitamins and direct thrombin inhibitors show promise for select populations.

Conclusions:

  • Secondary stroke prevention requires a comprehensive approach.
  • Novel pharmacotherapies enhance treatment strategies for at-risk individuals.
  • Updated recommendations guide the use of diverse interventions to minimize recurrent stroke.

More Related Videos

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique07:34

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique

Published on: December 15, 2023

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...